<DOC>
	<DOCNO>NCT01226316</DOCNO>
	<brief_summary>This study design investigate safety tolerability new drug , AZD5363 , patient advance cancer - identify dose schedule use future . This study also investigate body handle AZD5363 ( ie , quickly body absorbs remove drug ) . This study also investigate anti-tumour activity AZD5363 patient advance / metastatic breast , gynaecological cancer solid cancer bear either AKT1 / PIK3CA PTEN mutation .</brief_summary>
	<brief_title>Safety , Tolerability &amp; Potential Anti-cancer Activity Increasing Doses AZD5363 Different Treatment Schedules</brief_title>
	<detailed_description>A Phase I , Open-Label , Multicentre Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Anti-tumour Activity Ascending Doses AZD5363 Adaptable Dosing Schedules Patients Advanced Solid Malignancies .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Aged least 18 year . Parts A , B : The presence solid , malignant tumour , exclude lymphoma , resistance standard therapy standard therapy exist . ER+/HER2+ breast , ovarian , cervical , endometrial cancer , solid cancer , resistance standard therapy PIK3CA gene mutation ( Part C ) , AKT1 gene mutation ( Part D ) dysregulatory aberration PIK/AKT pathway ( Part D ) , advance metastatic ER+ positive breast cancer AKT1 gene mutation ( Part E ) advance metastatic ER+ positive breast cancer PTEN gene mutation ( Part F ) . The presence least one lesion accurately assess baseline CT , MRI plain Xray suitable repeat assessment . Estimated life expectancy 12 week . Estimated life expectancy 12 week . Clinically significant abnormality glucose metabolism . Spinal cord compression brain metastasis unless asymptomatic , treat stable ( require steroid ) . Evidence severe uncontrolled systemic disease , include active bleeding diatheses active infection include hepatitis B , C HIV . Evidence clinically significant cardiac abnormality , uncontrolled hypotension , leave ventricular ejection fraction lower limit normal site experience significant cardiac interventional procedure . A bad reaction AZD5363 drug similar structure class .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced solid malignancy , PIK3CA mutate , AKT1 mutate , PTEN mutation , PTEN alteration , metastatic , ER+ , breast , ovarian , endometrial , AZD5363 , AKT inhibitor ,</keyword>
</DOC>